4.99
-0.06(-1.19%)
Currency In USD
| Previous Close | 5.05 |
| Open | 5.05 |
| Day High | 5.12 |
| Day Low | 4.89 |
| 52-Week High | 6.55 |
| 52-Week Low | 0.73 |
| Volume | 177,843 |
| Average Volume | 297,828 |
| Market Cap | 319.62M |
| PE | -7.8 |
| EPS | -0.64 |
| Moving Average 50 Days | 4.47 |
| Moving Average 200 Days | 2.4 |
| Change | -0.06 |
If you invested $1000 in Galectin Therapeutics Inc. (GALT) 10 years ago, it would be worth $1,663.33 as of October 19, 2025 at a share price of $4.99. Whereas If you bought $1000 worth of Galectin Therapeutics Inc. (GALT) shares 5 years ago, it would be worth $1,827.84 as of October 19, 2025 at a share price of $4.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced participation in the
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 2
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hype